IDEAYA Q2 net loss $27.9M, cash $510.1M; starts Phase 2/3 registrational trial for darovasertib

IDEAYA Biosciences, Inc.

2023-Q2 EPS reported -$0.99 revenue$11,424,000

Net loss of $27.9M for Q2 2023; accumulated deficit $287.0M; cash and securities $510.1M, funding into 2027.
Initiated Phase 2/3 registrational trial for darovasertib/crizotinib in first-line HLA-A2(-) metastatic uveal melanoma.
First patient dosed in Amgen-sponsored Phase 1/2 trial of IDE397 (MAT2A) + AMG 193 in MTAP-deletion solid tumors.
Anticipating FDA IND clearance in Q3 2023 for GSK101 Pol Theta Helicase inhibitor; $7M milestone due from GSK.
Targeting Werner Helicase development candidate with GSK in H2 2023, with potential $3M milestone from GSK.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEAYA Biosciences, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.